Protein Kinase C (PKC, 76-93 kD) is a family of Ser/Thr specific protein kinases that perform key functions in numerous signalling pathways, in biological systems, through their various isoforms. The conventional PKC isoforms (cPKC) are PKC-α, β1, β2 and γ; activated by phosphatidylserine, calcium or phorbol esters. Proteolysis of PKC in vivo is thought to be mediated by calpains I and II. Calpains cleave PKC in the V3 hinge region to produce two distinct fragments, one comprising the N-terminal regulatory domain (30 kD) and the other fragment containing the C-terminal kinase domain (50 kD) that is catalytically active. Multiple functions such as, cellular and vascular regulations, angiogenesis, cell growth, apoptosis, changes in basement membrane thickness, extracellular matrix organisation, MAPK signalling, are attributed to PKC isoforms. These varied functions implicate PKC isoforms in cardiac hypertrophies and diabetic nephropathy and cardiovascular complications.
Anti-Protein Kinase C β2 antibody specifically recognizes an epitope located within the amino acid residues 660-673 at the C-terminal variable (V5) region of PKCβ2 (80 kDa).
The antibody shows no cross-reactivity with PKC peptides corresponding to C-terminal sequences from PKC β1 (658-671) and PKC γ (684-697) conjugated to BSA.
synthetic peptide corresponding to the C-terminal variable (V5) region (amino acids 660-673) of PKC β2.
Anti-Protein Kinase C β2 antibody may be used for immunoblotting at a working dilution of 1:8000 using rat brain cytosolic extract. It is suitable for protein microarray.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.